focus -WSS

focus

author：comprehensive 2025-09-03 14:43:49 - browse：2

Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Senate committee scrutinizes Medicare Advantage brokers

hotspot

WSS

Scientific mystery highlights the blind spots in genomics databases

NIH confirmation hearing shows politicization of research

Study: Black kids more likely to die after surgery than white kids

Alzheimer's risk factor APOE4 may be a distinct form of the disease

How climate

Why health workers in Gaza are injured or die at high rates

focus

focus

explore

The high cost of giving birth even with insurance

Insurer loopholes limit power of law against surprise medical bills

Trump demands the U.S. pay no more for drugs than other countries … again

Four alarming medical procedures we’re glad history forgot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Florida Supreme Court upholds state's abortion ban

Peter Hotez and the public health issue of online harassment

How climate

Sports medicine is finally prioritizing gender equality

Hundreds died while taking an arthritis drug, but nobody alerted patients

focus

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Solve the antibiotic resistance crisis with preventive drugs

Overprescribed: High cost isn't America's only drug problem

Republican states more likely to report Covid vaccine side effects

Impact of Dobbs ruling felt at reproductive medicine meeting

Mass General Brigham physicians react to latest merger step

knowledge

hotspot

entertainment

entertainment